A first-of-its-kind study compared preventative therapy efficacy between two groups: gene therapy alone and in combination with risdiplam or nusinersen. Dual therapy showed promise in independent sitting outcomes, but not in walking age or muscle disease progression prevention.
Researchers published safety and efficacy data for a novel nusinersen drug delivery method via subcutaneous intrathecal catheter system (SIC) for spinal muscular atrophy (SMA) patients. The study found improvements in arm and hand function, but no significant changes in motor scales or muscle force.
A new study summarizes over 30 years of clinical experience in treating glutaric acidemia type 1 (GA1), a rare and devastating metabolic disorder. The clinic's therapies have reduced brain injury risk by 83%, improving treatment outcomes for individuals with GA1.
A 30-year study on Crigler-Najjar syndrome reveals the clinical course of 28 individuals with high bilirubin levels, demonstrating the effectiveness of phototherapy and liver transplantation. Early intervention is critical, and treatment delays increase brain damage risk.
The Clinic for Special Children's SMA Prevention Readiness program successfully identified 318 carriers and 9 affected couples, treating 3 infants with gene therapy. The program's cascade testing approach was effective in detecting genetic risk, leveraging funding from biotech company AveXis.
A 30-year study details clinical course of 184 individuals with genetically diverse forms of MSUD, showing increased survival and hospitalization rates. Despite advances in care, patients continue to suffer from cognitive and psychiatric disabilities, highlighting the need for safer and more effective disease-modifying interventions.
A comprehensive study on ST3GAL5 deficiency, a rare genetic disorder affecting ganglioside synthesis, provides insights into its clinical characterization and natural course. Researchers hope to develop pre-symptomatic therapies using gene replacement techniques.
A novel multisystem disorder has been identified due to bi-allelic variants in the CCDC47 gene, affecting individuals with symptoms such as woolly hair, liver dysfunction, and global developmental delay. The study demonstrates the importance of CCDC47 in normal development and highlights the need for further research into this condition.
Researchers identified a novel missense mutation in tyrosyl-tRNA synthetase (YARS) causing severe recessive disorder. The study found that affected individuals exhibited poor growth, developmental delay, and various organ dysfunctions, including liver disease, pancreatic insufficiency, and hearing loss.
A natural history study provides the first comprehensive clinical description of spinal muscular atrophy (SMA) within Amish and Mennonite communities, correlating haplotypes and SMN2 copy number with disease severity. The study reveals differences in disease expression and survival between genotypes with varying numbers of SMN2 copies.
Researchers have developed a new subcutaneous intrathecal catheter system (SIC) to deliver nusinersen to SMA patients, significantly reducing hospital stays and costs. The SIC method allows for faster and more efficient administration of the drug, with an average hospital stay of less than 55 hours.
A new natural history study of Amish nemaline myopathy provides a platform for exploring gene replacement therapy. The study's findings show promise for treating the lethal disorder, which is linked to a mutation of the TNNT1 gene.